UMass Amherst Chemists Design 'Tunable,' Cloaked, Toxin Delivery System to Kill Tumors from Within

UMass Amherst Chemists Design ‘Tunable,' Cloaked, Toxin Delivery System to Kill Tumors from Within

Oct. 3, 2010

Contact: Janet Lathrop
413/545-0444


AMHERST, Mass. - Researchers led by University of Massachusetts Amherst chemist Vincent Rotello have demonstrated that they can deliver a dormant toxin into a specific site such as a tumor for anti-cancer therapy, then chemically trigger the toxin to de-cloak and attack from within. It holds promise as a "complex and sophisticated" synthetic, therapeutic drug delivery system for living cells.

A paper describing the new host-guest chemistry approach by Rotello and colleagues, with Lyle Isaacs at the University of Maryland, appears in the current issue of Nature Chemistry.

As Rotello explains, "Supramolecular chemistry focuses on understanding what forces make molecules stick together, and using these forces to control the assembly of functional systems. This assembly process is much like Lego blocks, where bumps and dimples interact to hold biomolecules like DNA and proteins together."

Specifically, Rotello and colleagues covered specialized gold nanoparticles with ligand or binding molecules (the bump) that made the particles toxic. These ligands, however, also can strongly bind to a hollow, bowl-shaped molecule (the dimple to which the bump sticks) called a cucurbituril that can make the particle non-toxic. When the gold nanoparticles are introduced into living cells, they lie dormant. The researchers then use another molecule that binds strongly to the dimple-shaped cucurbiturils, pulling them away from the gold nanoparticle so it becomes uncloaked and toxic.

"This triggered toxicity opens up new directions for controlled chemotherapeutics, where toxicity can be tuned by and directed through choice and amount of added activator," Rotello says. "They would be capable of achieving higher levels of site-specific activity with reduced collateral damage to surrounding healthy cells."

His research group is currently exploring this strategy in cells and will be moving to in vivo systems soon to thoroughly explore issues related to real-world application of the system.

 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.